Table 1.
Correlation between PLEKHA4 expression and clinicopathologic factors in the TCGA cohort.
| Characteristic | Low expression of PLEKHA4 | High expression of PLEKHA4 | p |
|---|---|---|---|
| n | 264 | 264 | |
| WHO grade, n (%) | < 0.001 | ||
| G2 | 143 (30.6%) | 81 (17.3%) | |
| G3 | 94 (20.1%) | 149 (31.9%) | |
| IDH status, n (%) | < 0.001 | ||
| WT | 13 (2.5%) | 84 (16%) | |
| Mut | 249 (47.4%) | 179 (34.1%) | |
| 1p/19q codeletion, n (%) | < 0.001 | ||
| Codel | 147 (27.8%) | 24 (4.5%) | |
| Noncodel | 117 (22.2%) | 240 (45.5%) | |
| Age, n (%) | 0.433 | ||
| < =40 | 137 (25.9%) | 127 (24.1%) | |
| > 40 | 127 (24.1%) | 137 (25.9%) | |
| Primary therapy outcome, n (%) | 0.002 | ||
| PD | 38 (8.3%) | 72 (15.7%) | |
| SD | 78 (17%) | 68 (14.8%) | |
| PR | 31 (6.8%) | 33 (7.2%) | |
| CR | 80 (17.5%) | 58 (12.7%) | |
| Gender, n (%) | 0.484 | ||
| Female | 124 (23.5%) | 115 (21.8%) | |
| Male | 140 (26.5%) | 149 (28.2%) | |
| Age, median (IQR) | 40 (33, 52) | 41 (32, 54.25) | 0.575 |